Drug hanging network and trading rules will unify the nation

Drug hanging network and trading rules will unify the nation

Source: Sai Blue/Cefei Heroes

Recently, the "Public Response of the Public Answers to the Fifth Session of the Thirteenth National People's Congress No. 8013" issued by the National Medical Insurance Bureau clearly states that the State Medical Insurance Bureau is studying and improving the mechanism of the centralized procurement platform and promoting the establishment of a unified nationwide hanging network. And trading rules.

It is not difficult to see that this is the national level blowing in advance. From various perspectives, the implementation of the national unified hanging network is only a matter of time. The author tries to analyze multi -dimensional deductions from policy direction, technical preparation, implementation time and scope, and rules.

01

Policy direction

At present, the more unified management of the pharmaceutical market access is the direction of the current competent authority.

The regulations of the medical insurance catalog, the formulation of basic drug directory, the registration and approval of drugs, and the expansion of the national collection of drugs are all showing that the medical reform of the central government's management of "central government management, local governments find pilot and implementation" gradually landed.

However, national -level centralized procurement can only be a major way of purchasing drugs for medical institutions, and it is impossible to be the entire way.

02

Technical preparations

In the first half of 2019, the National Medical Insurance Administration had bid three times for the "Medical Security Information Platform Construction Engineering Application Software" project, with a bid amount of 16.941 million yuan, and 9 bidders, including: build national medical insurance drugs and medical consumables recruitment for recruitment Management subsystems provide support for the National Medical Security Bureau with the support of national drugs and medical consumables.

From this point of view, the state will use a unified platform during the transaction matching or bidding stage. However, the service provider of the trading platform may not be used to continue to use online transactions in various provinces. Wait until the national background is opened to achieve data capture. Now most of the pharmaceutical consumables have been provided uniformly, and the data standards are the same, and it is not a problem to realize that the data cross -platform is connected.

03

Implementation time and scope

The national unified platform hanging network is expected to be realized too late. As of now, the old transaction (bidding) platforms of various provinces have not stopped using it, and the drugs of all provinces have already achieved online matching and online transactions. At present, the progress of consumables on the Internet is uneven, and the provinces are still catching up with the progress of the entire product of consumables.

At present, the national unified platform hangs on the network, and first transaction from national collection and local collection products and Tong GM products. Renewal (matching transactions) and other work are the simplest and easy to do. The rules are clear and no need to discuss anything.

However, it is expected that the quotation of Guotai and the bid opening will not be temporarily discounted by any company's trading system. After all, the Internet is far from being sealed, simple, effective, and clear.

04

Rule analysis

If you want to unify the platform, we must organize a centralized price to achieve a reasonable price difference between different levels of the same product area; realize the reasonable price difference between different specifications, different models (dosage, materials) of the same (similar) products; (Consumption) Reasonable price difference and so on.

It is not easy to establish the rules that most people are satisfied with in a short time. The main rules are as follows:

1. Quality level (distinguish between original research and consistency evaluation; ordinary level)

2. The benchmark price (the lowest price of the country; the new product refer to the cost of treatment expenses)

3. The difference between the difference (the specifications of the same product, the difference between the difference between the dosage form)

4. Product grouping (group form and name according to the medical insurance directory)

5. The price difference between the same product (the lowest price of the same product is 1.8 times)

The country's implementation of unified rules and unified platforms for drug consumables. It has matured in policies and technical conditions. In 2023, steps and products may be gradually implemented. Are you ready?

Disclaimer: This article is the content of Yaozhi.com, and the copyright of the pictures and text belongs to the original author. The purpose of reprinting is to pass more information, which does not represent the viewpoint of this platform. If the content, copyright and other issues are involved in the work, please leave a message on this platform, and we will delete it as soon as possible.

- END -